EUVIMEDEUVIMED entdecken
Fallbericht

Pembrolizumab-induced peripheral nervous system damage: A combination of myositis/myasthenia overlap syndrome and motor axonal polyneuropathy

Çakar Arman, Kamaci Ibrahim, Orhan Kocasoy Elif, Durmuş Hacer, Parman Yeşim

Ideggyógyászati szemle · 2023

DOI: 10.18071/isz.76.0422 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Ideggyógyászati szemle, 2023. Verfasst von Çakar Arman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neuromuscular Unit, Neurology Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Myositis, Polyneuropathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction – Immune-checkpoint inhibitors (ICI) are effective drugs in cancer treatment that block immune checkpoints and stimulate an attack on cancer cells. However, various side effects were reported with ICIs. Peripheral nervous system (PNS) side effects are three times more frequent than those in the central nervous system. Case report – A 63-year-old male patient was admitted to our department with a 10-day history of dyspnea, diplopia, and generalized weakness. He had a diagnosis of non-small cell lung cancer, which was treated with pembrolizumab. His neurological symptoms appeared one week after the second course of pembrolizumab, and gradually worsened. His neurological examination showed nasal speech, bilateral ptosis, tongue and neck flexor weakness, prominent asymmetrical upper limb weakness, and mild lower limb weakness. Deep tendon reflexes and sensory examination were normal. He had an elevated creatine kinase level (4430 U/L). Needle electromyography (EMG) showed a myopathic pattern, and single fiber EMG demonstrated an increased jitter in the right frontal muscle. Pembrolizumab treatment was discontinued, and intravenous methylprednisolone followed by intravenous immunoglobulin (IVIg) were initiated. His symptoms gradually improved. However, his weakness began to worsen after a month, and repeated nerve conduction studies showed a predominantly motor axonal polyneuropathy. Thereafter, the patient was treated with IVIg infusions (0.4 g/every two weeks) to maintain his motor function. Conclusion – Our case showed that ICIs could simultaneously or sequentially cause damage in multiple domains of the PNS. Early recognition of these adverse events is essential since the outcome is favorable with rapid cessation of the causative ICI and administration of immune-modulator treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMyositisPolyneuropathiesMaleHumansMiddle AgedImmunoglobulins, IntravenousMuscle WeaknessSyndromePeripheral Nervous SystemAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

immune checkpoint inhibitorintravenous immunoglobulinmyasthenia gravismyocarditispolyneuropathy

Substanzen

Immunoglobulins, IntravenouspembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Neuromuscular Unit, Neurology Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Neurology Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Zitieren

APA

Arman, Ç., Ibrahim, K., Elif, O. K., Hacer, D., & Yeşim, P. (2023). Pembrolizumab-induced peripheral nervous system damage: A combination of myositis/myasthenia overlap syndrome and motor axonal polyneuropathy. Ideggyógyászati szemle. https://doi.org/10.18071/isz.76.0422

Vancouver

Arman Ç, Ibrahim K, Elif OK, Hacer D, Yeşim P. Pembrolizumab-induced peripheral nervous system damage: A combination of myositis/myasthenia overlap syndrome and motor axonal polyneuropathy. Ideggyógyászati szemle. 2023. doi:10.18071/isz.76.0422

BibTeX
@article{Arman2023,
  author = {Arman, Çakar and Ibrahim, Kamaci and Elif, Orhan Kocasoy and Hacer, Durmuş and Yeşim, Parman},
  title = {Pembrolizumab-induced peripheral nervous system damage: A combination of myositis/myasthenia overlap syndrome and motor axonal polyneuropathy},
  journal = {Ideggyógyászati szemle},
  year = {2023},
  doi = {10.18071/isz.76.0422}
}
Kostenlos starten →